Next Article in Journal
Preoperative Ascorbic Acid Levels in Proximal Femur Fracture Patients Have No Postoperative Clinical Impact, While Ascorbic Acid Levels upon Discharge Have a Major Effect on Postoperative Outcome
Previous Article in Journal
Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy
Previous Article in Special Issue
Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
Open AccessArticle

Immunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin–Phosphorylcholine

1
Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 52620, Israel
2
Department of Gastroenterology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6423906, Israel
3
Institute of Pathology, Sheba Medical Center Tel Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 52620, Israel
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(1), 65; https://doi.org/10.3390/jcm9010065
Received: 15 October 2019 / Revised: 10 December 2019 / Accepted: 11 December 2019 / Published: 26 December 2019
(This article belongs to the Special Issue Ulcerative Colitis: Current and Emerging Treatment Strategies)
Helminths or their products can immunomodulate the host immune system, and this phenomenon may be applied as the basis of new anti-inflammatory treatments. Previously, we have shown the efficacy of tuftsin–phosphorylcholine (TPC), based on a helminth product, in four animal models of autoimmune diseases: arthritis, colitis, systemic lupus erythematosus, and experimental autoimmune encephalomyelitis. We demonstrated that TPC reduced inflammatory process ex vivo in peripheral blood lymphocytes (PBLs) and in biopsies from giant-cell arteritis. In the present study, we assessed the therapeutic potential of TPC treatment on a chronic colitis murine model. C57BL/6 mice with chronic colitis were treated with TPC after the third cycle of 2% dextran sodium sulfate (DSS). Oral TPC treatment resulted in amelioration of the colitis clinical manifestations exemplified by reduced disease activity index (DAI) score, expansion of mesenteric lymph nodes (MLN) T regulatory cells (shown by Fluorescence Activated Cell Sorting (FACS)), significant reduction in the expression of pro-inflammatory cytokines (IL-1β, IL17, IL-6, TNFα), and elevation in the expression of anti-inflammatory cytokine IL-10 (shown by RT-PCR). This study demonstrated the potential immunomodulatory effects of oral administration of TPC in a chronic colitis murine model. Further clinical trials are needed in order to evaluate this novel approach for the treatment of patients with inflammatory bowel disease. View Full-Text
Keywords: inflammatory bowel disease; colitis; phosphorylcholine; tuftsin inflammatory bowel disease; colitis; phosphorylcholine; tuftsin
Show Figures

Figure 1

MDPI and ACS Style

Ben-Ami Shor, D.; Lachnish, J.; Bashi, T.; Dahan, S.; Shemer, A.; Segal, Y.; Shovman, O.; Halpert, G.; Volkov, A.; Barshack, I.; Amital, H.; Blank, M.; Shoenfeld, Y. Immunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin–Phosphorylcholine. J. Clin. Med. 2020, 9, 65.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop